睿知中国医院研究地图
候选清单

正在招募B 细胞急性淋巴细胞白血病不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06678282,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Refractory B-ALL: those who did not achieve complete remission after 2 courses of standard induction regimen chemotherapy, or those who did not achieve complete remission after first-line or multi-line salvage chemotherapy;

    入选标准第 5 条

    Relapsed B-ALL: relapse within 12 months after first remission, or relapse after first-line / multi-line salvage chemotherapy;

    入选标准第 6 条

    Relapse after autologous or allogeneic hematopoietic stem cell transplantation; In addition, patients with Philadelphia chromosome positive (Ph +) should be relapsed after at least two tyrosine kinase inhibitors (TKI) treatment, or they could not tolerate TKI therapy, or have a t315i mutation, resistant to TKI drugs.

    入选标准第 7 条

    Subjects who have received other study drugs within 30 days before screening, or are still in the washout period;

    排除标准第 3 条

    Patients who have previously received any anti-CD19 / anti-Cluster of Differentiation 3(CD3) therapy or any other anti-CD19 therapy (except for those with normal T cell numbers and function and with CD19-positive tumors);

    排除标准第 4 条

    Patients who have been previously treated with any gene therapy product, including Chimeric Antigen Receptor T(CAR-T) therapy (except patients who do not have CAR-T cells in vivo and have normal T cell number and function and are with CD19 positive tumors);

    排除标准第 5 条

    Carcinoma in situ of cervical cancer or breast cancer, after curative treatment, showed no signs of recurrence for at least 3 years before the study;

    排除标准第 12 条

  3. Baseline Eastern Cooperative Oncology Group(ECOG) score was 0-1;

    入选标准第 12 条

  4. Glutamic aminotransferase (ALT) ≤3 times upper limit of normal (ULN);

    入选标准第 14 条

    Grass aminotransferase (AST) ≤3 times ULN;

    入选标准第 15 条

    Total bilirubin ≤1.5 times ULN;

    入选标准第 16 条

    Serum creatinine ≤ 1.5 times ULN, or creatinine clearance ≥ 60 mL/min;

    入选标准第 17 条

    Absolute neutrophil count (ANC)>1.000 / mm3;

    入选标准第 22 条

    Platelet≥50.000/mm3;

    入选标准第 24 条

    Hemoglobin>8.0 g/dl;

    入选标准第 25 条

  5. At least one measurable lesion was imaging for relapsed or refractory B cell lymphoma, long diameter of> 15mm, or extranodal lesion of> 10mm, along with a positive Positron Emission Tomography - Computed Tomography(PET-CT) examination.

    入选标准第 10 条

  6. Subjects with active hepatitis B (defined as Hepatitis B Virus(HBV) DNA test value> 500 IU / mL) or hepatitis C (HCV RNA positive); subjects with HIV positive or treponema pallidum positive;

    排除标准第 7 条

    The primary malignancy has been completely removed and is in complete remission for 5 years.

    排除标准第 13 条

  7. Female subjects in pregnant or lactating, or women with planned pregnancy within 2 years after JY231 infusion or male partner with planned pregnancy within 2 years after JY231 infusion;

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06678282,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subject voluntarily sign informed consent and are willing and able to comply with all trial requirements;
  2. Age is 18-75 years old and gender is not limited;
  3. Malignancy cells in bone marrow or peripheral blood are Cluster of Differentiation 19 - positive(CD19+) detected by flow cytometric analysis;
  4. Meet the clinical criteria for relapsed or refractory B-cell lymphoma, including: indolent lymphoma (iNHL), such as follicular lymphoma (FL) and marginal zone lymphoma (MZL); aggressive B-cell lymphoma, like diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and T-rich lymphocyte-bearing large B-cell lymphoma (TCRBCL), or have a diagnosis of acute B-lymphocytic leukemia (B-ALL) and meet one of the following conditions:
  5. Refractory B-ALL: those who did not achieve complete remission after 2 courses of standard induction regimen chemotherapy, or those who did not achieve complete remission after first-line or multi-line salvage chemotherapy;
  6. Relapsed B-ALL: relapse within 12 months after first remission, or relapse after first-line / multi-line salvage chemotherapy;
  7. Relapse after autologous or allogeneic hematopoietic stem cell transplantation; In addition, patients with Philadelphia chromosome positive (Ph +) should be relapsed after at least two tyrosine kinase inhibitors (TKI) treatment, or they could not tolerate TKI therapy, or have a t315i mutation, resistant to TKI drugs.
  8. Morphological examination of bone marrow cells showed the proportion of primitive and naive lymphocytes was> 5%;
  9. No Hematopoietic Stem Cell Transplantation(HSCT) within 6 months before enrollment;
  10. At least one measurable lesion was imaging for relapsed or refractory B cell lymphoma, long diameter of> 15mm, or extranodal lesion of> 10mm, along with a positive Positron Emission Tomography - Computed Tomography(PET-CT) examination.
  11. More than 12 weeks of expected survival period
  12. Baseline Eastern Cooperative Oncology Group(ECOG) score was 0-1;
  13. Adequate organ function (criteria regarding liver and kidney function can be moderately relaxed):
  14. Glutamic aminotransferase (ALT) ≤3 times upper limit of normal (ULN);
  15. Grass aminotransferase (AST) ≤3 times ULN;
  16. Total bilirubin ≤1.5 times ULN;
  17. Serum creatinine ≤ 1.5 times ULN, or creatinine clearance ≥ 60 mL/min;
  18. Indoor oxygen saturation ≥ 92%;
  19. Left ventricular ejection fraction (LVEF)≥55%, echocardiography confirmed no pericardial effusion and no clinically significant ECG findings;
  20. There is no clinically significant pleural effusion;
  21. Adequate bone marrow reserve without transfusion, defined as:
  22. Absolute neutrophil count (ANC)>1.000 / mm3;
  23. Absolute lymphocyte count (ALC)≥ 300 / mm3;
  24. Platelet≥50.000/mm3;
  25. Hemoglobin>8.0 g/dl;
  26. Subjects using the following drugs need to meet the following conditions:
  27. Steroids: The therapeutic dose of steroids must be stopped 72 hours before JY231 infusion. However, physiological alternative doses of steroids are allowed;
  28. Immunosuppression: Any immunosuppressive drug must be stopped at ≥4 weeks prior to enrollment;
  29. Antiproliferative therapy other than lymphodepletion chemotherapy within two weeks of infusion;
  30. Cluster of Differentiation 20(CD20) antibody-related therapy must be stopped within 4 weeks before infusion or 5 half-lives after the CD20 antibody;
  31. CNS disease prophylaxis must be stopped 1 week before JY231 infusion (e. g. intrathecal methotrexate).

排除标准:Exclusion Criteria:

  1. Subjects with active cerebrospinal fluid malignant cells or brain metastases, or subjects with active central nervous system (CNS) lymphoma, or CNS leukaemia;
  2. Subjects with a history of active CNS disease, such as seizures, cerebrovascular ischemia / hemorrhage, dementia, cerebellar disease, or any autoimmune disease associated with CNS involvement;
  3. Subjects who have received other study drugs within 30 days before screening, or are still in the washout period;
  4. Patients who have previously received any anti-CD19 / anti-Cluster of Differentiation 3(CD3) therapy or any other anti-CD19 therapy (except for those with normal T cell numbers and function and with CD19-positive tumors);
  5. Patients who have been previously treated with any gene therapy product, including Chimeric Antigen Receptor T(CAR-T) therapy (except patients who do not have CAR-T cells in vivo and have normal T cell number and function and are with CD19 positive tumors);
  6. Subjects with radiation therapy within 2 weeks prior to the infusion;
  7. Subjects with active hepatitis B (defined as Hepatitis B Virus(HBV) DNA test value> 500 IU / mL) or hepatitis C (HCV RNA positive); subjects with HIV positive or treponema pallidum positive;
  8. Subjects with uncontrolled acute life-threatening bacterial, viral, or fungal infection (e. g. positive blood culture 72 hours before infusion);
  9. Subjects with unstable angina pectoris and / or myocardial infarction within the 6 months prior to screening;
  10. Subjects with concurrent or previously diagnosed with other malignancies, except for the patients under following conditions:
  11. Well treated basal cells, papillary thyroid carcinoma, squamous cell carcinoma (adequate wound healing is required before enrollment into this study);
  12. Carcinoma in situ of cervical cancer or breast cancer, after curative treatment, showed no signs of recurrence for at least 3 years before the study;
  13. The primary malignancy has been completely removed and is in complete remission for 5 years.
  14. Arrhythmic subjects without medical management control;
  15. Subjects receiving oral anticoagulation within 1 week before JY231 injection infusion;
  16. Having active neurological autoimmune or inflammatory conditions (such as Guillain-Barre syndrome, amyotrophic lateral sclerosis);
  17. Female subjects in pregnant or lactating, or women with planned pregnancy within 2 years after JY231 infusion or male partner with planned pregnancy within 2 years after JY231 infusion;
  18. Subjects with taboo study procedures or other medical conditions that may put them at unacceptable risk according to the investigator's judgment and / or clinical criteria.

引自 ClinicalTrials.gov, NCT06678282, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06678282,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06678282